HCV and HCC: Clinical Update and a Review of HCC-Associated Viral Mutations in the Core Gene

Jawad Ahmad; Francis J. Eng; Andrea D. Branch

doi:10.1055/s-0031-1297924

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2011; 31(4): 347-355
DOI: 10.1055/s-0031-1297924

HCV and HCC: Clinical Update and a Review of HCC-Associated Viral Mutations in the Core Gene

Jawad Ahmad¹ , Francis J. Eng¹ , Andrea D. Branch¹

¹Division of Liver Diseases, The Mount Sinai School of Medicine, New York, New York

Abstract

ABSTRACT

Hepatocellular carcinoma (HCC) is a common cause of cancer-related mortality. The worldwide incidence of HCC and the hepatitis C virus (HCV) has increased over several decades suggesting an etiologic link. Progress has been made recently in several fields related specifically to HCV and HCC. The epidemiology has been better characterized, surveillance and treatment programs have been instituted, and data have emerged detailing the effect of other risk factors for HCC in patients with HCV. Studies of HCV-related HCC suggest differences in oncogenic potential according to genotype and mutations in the viral sequence. These same mutations are associated with interferon treatment failure, insulin resistance, and expression of HCV minicore proteins. These viral mutations provide a focus for investigations into the molecular basis of HCV-related oncogenesis, which may lead to improved diagnostic tests for early (curable) HCC and to interventions to prevent, and/or greatly retard, the oncogenic process.

KEYWORDS

Hepatitis C virus - hepatocellular carcinoma - core protein - minicore

Full Text

References

REFERENCES

1 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340 (10) 745-750
2 Kew M C. Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med. 1996; 16 (2) 395-406
3 Kim C M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991; 351 (6324) 317-320
4 Nishioka K, Watanabe J, Furuta S et al.. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer. 1991; 67 (2) 429-433
5 Bruix J, Barrera J M, Calvet X et al.. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989; 2 (8670) 1004-1006
6 Colombo M, Kuo G, Choo Q L et al.. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989; 2 (8670) 1006-1008
7 Altekruse S F, McGlynn K A, Reichman M E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27 (9) 1485-1491
8 Dominitz J A, Boyko E J, Koepsell T D et al.. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005; 41 (1) 88-96
9 Kanwal F, Hoang T, Kramer J R et al.. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011; 140 (4) 1182-1188, e1
10 Sangiovanni A, Prati G M, Fasani P et al.. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006; 43 (6) 1303-1310
11 Tanaka Y, Kurbanov F, Mano S et al.. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006; 130 (3) 703-714
12 Tanaka H, Imai Y, Hiramatsu N et al.. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008; 148 (11) 820-826
13 Bruix J, Sherman M. American Association for the Study of Liver Diseases . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53 (3) 1020-1022
14 Davila J A, Morgan R O, Richardson P A, Du X L, McGlynn K A, El-Serag H B. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010; 52 (1) 132-141
15 Davila J A, Henderson L, Kramer J R et al.. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011; 154 (2) 85-93
16 Santi V, Trevisani F, Gramenzi A Italian Liver Cancer (ITA.LI.CA) Group et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53 (2) 291-297
17 Lok A S, Sterling R K, Everhart J E HALT-C Trial Group et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010; 138 (2) 493-502
18 Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli M U. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007; 46 (5) 1350-1356
19 Lee M H, Yang H I, Lu S N et al.. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol. 2010; 28 (30) 4587-4593
20 Kumada T, Toyoda H, Kiriyama S et al.. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol. 2009; 50 (4) 729-735
21 Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S. JPHC Study Group . Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev. 2009; 18 (1) 26-32
22 Maki A, Kono H, Gupta M et al.. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 2007; 14 (3) 1182-1190
23 Suruki R Y, Mueller N, Hayashi K et al.. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 2006; 15 (12) 2521-2525
24 Dienstag J L, Ghany M G, Morgan T R HALT-C Trial Group et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011; 54 (2) 396-405
25 Hoefs J C, Shiffman M L, Goodman Z D, Kleiner D E, Dienstag J L, Stoddard A M. HALT-C Trial Group . Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C trial. Gastroenterology. 2011; 141 (3) 900-908 e1-e2
26 Asahina Y, Tsuchiya K, Tamaki N et al.. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010; 52 (2) 518-527
27 Hassan M M, Spitz M R, Thomas M B et al.. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol. 2009; 50 (2) 334-341
28 Lok A S, Everhart J E, Di Bisceglie A M, Kim H Y, Hussain M, Morgan T R. HALT-C Trial Group . Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011; 54 (2) 434-442
29 Ikeda K, Marusawa H, Osaki Y et al.. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007; 146 (9) 649-656
30 Gelatti U, Covolo L, Franceschini M Brescia HCC Study Group et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol. 2005; 42 (4) 528-534
31 Inoue M, Yoshimi I, Sobue T, Tsugane S. JPHC Study Group . Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst. 2005; 97 (4) 293-300
32 Lambrecht R W, Sterling R K, Naishadham D HALT-C Trial Group et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011; 140 (5) 1490-1500, e3
33 Nahon P, Sutton A, Rufat P et al.. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology. 2008; 134 (1) 102-110
34 Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S. JPHC Study Group . Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int J Cancer. 2009; 124 (7) 1644-1649
35 Lai M S, Hsieh M S, Chiu Y H, Chen T H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006; 43 (6) 1295-1302
36 N'Kontchou G, Paries J, Htar M T et al.. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006; 4 (8) 1062-1068
37 Veldt B J, Chen W, Heathcote E J et al.. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008; 47 (6) 1856-1862
38 Ohishi W, Fujiwara S, Cologne J B et al.. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2008; 17 (4) 846-854
39 Ohki T, Tateishi R, Sato T et al.. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008; 6 (4) 459-464
40 Chen C L, Yang H I, Yang W S et al.. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008; 135 (1) 111-121
41 Inoue M, Kurahashi N, Iwasaki M Japan Public Health Center-based Prospective Study Group et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 2009; 20 (5) 741-750
42 Rossi M, Lipworth L, Maso L D et al.. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol. 2009; 20 (10) 1736-1740
43 Nkontchou G, Bastard J P, Ziol M et al.. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol. 2010; 53 (5) 827-833
44 Lok A S, Seeff L B, Morgan T R HALT-C Trial Group et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009; 136 (1) 138-148
45 Lok A S, Everhart J E, Wright E C HALT-C Trial Group et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011; 140 (3) 840-849, quiz e12
46 Shiffman M L, Morishima C, Dienstag J L HALT-C Trial Group et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009; 137 (6) 1986-1994
47 Morgan T R, Ghany M G, Kim H Y HALT-C Trial Group et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010; 52 (3) 833-844
48 Cardoso A C, Moucari R, Figueiredo-Mendes C et al.. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010; 52 (5) 652-657
49 Bruix J, Poynard T, Colombo M EPIC3 Study Group et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011; 140 (7) 1990-1999
50 Tanimoto Y, Tashiro H, Aikata H et al.. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol. 2011; Epub ahead of print
51 Burd E M. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 16 (1) 1-17
52 Raimondi S, Bruno S, Mondelli M U, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009; 50 (6) 1142-1154
53 Ray R B, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology. 2000; 271 (1) 197-204
54 Shan Y, Chen X G, Huang B, Hu A B, Xiao D, Guo Z M. Malignant transformation of the cultured human hepatocytes induced by hepatitis C virus core protein. Liver Int. 2005; 25 (1) 141-147
55 Moriya K, Fujie H, Shintani Y et al.. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998; 4 (9) 1065-1067
56 Naas T, Ghorbani M, Alvarez-Maya I et al.. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol. 2005; 86 (Pt 8) 2185-2196
57 Li Z H, Tang Q B, Wang J et al.. Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappaB pathway. J Gastroenterol Hepatol. 2010; 25 (7) 1315-1320
58 Chen R F, Li Z H, Liu R Y, Kong X H, Tang Q B, Wang J. Malignant transformation of the cultured human normal biliary tract epithelial cells induced by hepatitis C virus core protein. Oncol Rep. 2007; 17 (1) 105-110
59 Jin D Y, Wang H L, Zhou Y et al.. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J. 2000; 19 (4) 729-740
60 Smirnova I S, Aksenov N D, Kashuba E V et al.. Hepatitis C virus core protein transforms murine fibroblasts by promoting genomic instability. Cell Oncol. 2006; 28 (4) 177-190
61 El-Serag H B, Rudolph K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132 (7) 2557-2576
62 Bartosch B, Thimme R, Blum H E, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol. 2009; 51 (4) 810-820
63 Fishman S L, Factor S H, Balestrieri C et al.. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res. 2009; 15 (9) 3205-3213
64 Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol. 2002; 40 (10) 3625-3630
65 Rüster B, Zeuzem S, Krump-Konvalinkova V et al.. Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J Med Virol. 2001; 63 (2) 128-134
66 Delhem N, Sabile A, Gajardo R et al.. Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. Oncogene. 2001; 20 (41) 5836-5845
67 Horie C, Iwahana H, Horie T et al.. Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. Biochem Biophys Res Commun. 1996; 218 (3) 674-681
68 Alam S S, Nakamura T, Naganuma A et al.. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. Acta Med Okayama. 2002; 56 (3) 141-147
69 Takahashi K, Iwata K, Matsumoto M et al.. Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the ‘progression score’ revisited. Hepatol Res. 2001; 20 (2) 161-171
70 Hung C H, Chen C H, Lee C M et al.. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat. 2008; 15 (1) 58-65
71 Akuta N, Suzuki F, Kawamura Y et al.. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology. 2007; 46 (5) 1357-1364
72 Nakamoto S, Imazeki F, Fukai K et al.. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol. 2010; 52 (1) 72-78
73 Kobayashi M, Akuta N, Suzuki F et al.. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol. 2010; 82 (1) 41-48
74 Donlin M J, Cannon N A, Yao E Virahep-C Study Group et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007; 81 (15) 8211-8224
75 Enomoto N, Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology. 2010; 53 (1) 66-69
76 Okanoue T, Itoh Y, Hashimoto H et al.. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009; 44 (9) 952-963
77 Akuta N, Suzuki F, Kawamura Y et al.. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007; 46 (3) 403-410
78 Mori N, Imamura M, Kawakami Y Hiroshima Liver Study Group et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol. 2009; 81 (4) 640-649
79 Akuta N, Suzuki F, Hirakawa M et al.. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009; 81 (3) 452-458
80 Akuta N, Suzuki F, Kawamura Y et al.. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007; 79 (11) 1686-1695
81 Akuta N, Suzuki F, Kawamura Y et al.. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007; 50 (5) 361-368
82 Akuta N, Suzuki F, Sezaki H et al.. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006; 78 (1) 83-90
83 Akuta N, Suzuki F, Hirakawa M et al.. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol. 2009; 81 (6) 1032-1039
84 Funaoka Y, Sakamoto N, Suda G et al.. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol. 2011; 85 (12) 5986-5994
85 Fraser C S, Doudna J A. Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol. 2007; 5 (1) 29-38
86 Fukushi S, Katayama K, Kurihara C et al.. Complete 5′ noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA. Biochem Biophys Res Commun. 1994; 199 (2) 425-432
87 Hellen C U, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 2001; 15 (13) 1593-1612
88 Honda M, Ping L H, Rijnbrand R C et al.. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology. 1996; 222 (1) 31-42
89 Kieft J S, Zhou K, Jubin R, Doudna J A. Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA. 2001; 7 (2) 194-206
90 Otto G A, Puglisi J D. The pathway of HCV IRES-mediated translation initiation. Cell. 2004; 119 (3) 369-380
91 Wang C, Sarnow P, Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol. 1993; 67 (6) 3338-3344
92 McMullan L K, Grakoui A, Evans M J et al.. Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A. 2007; 104 (8) 2879-2884
93 Vassilaki N, Friebe P, Meuleman P et al.. Role of the hepatitis C virus core + 1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. J Virol. 2008; 82 (23) 11503-11515
94 Tuplin A, Evans D J, Simmonds P. Detailed mapping of RNA secondary structures in core and NS5B-encoding region sequences of hepatitis C virus by RNase cleavage and novel bioinformatic prediction methods. J Gen Virol. 2004; 85 (Pt 10) 3037-3047
95 Walewski J L, Gutierrez J A, Branch-Elliman W et al.. Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA. 2002; 8 (5) 557-571
96 Branch A D, Stump D D, Gutierrez J A, Eng F, Walewski J L. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis. 2005; 25 (1) 105-117
97 Eng F J, Walewski J L, Klepper A L et al.. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol. 2009; 83 (7) 3104-3114
98 Ogura S, Akuta N, Hirakawa M et al.. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology. 2009; 52 (4) 179-188
99 Eng F J, Yusuke Y, Kopp M et al.. Viral mutations that predict treatment failure and liver cancer control expression of the newly-discovered HCV minicore proteins. Paper presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29–November 2, 2010; Boston, MA
100 Chen H M, Tanaka N, Mitani Y et al.. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci. 2009; 100 (3) 449-456
101 Fridman A L, Tainsky M A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene. 2008; 27 (46) 5975-5987
102 Lindkvist A, Ivarsson K, Jernberg-Wiklund H, Paulsson-Karlsson Y. Interferon-induced sensitization to apoptosis is associated with repressed transcriptional activity of the hTERT promoter in multiple myeloma. Biochem Biophys Res Commun. 2006; 341 (4) 1141-1148

Jawad AhmadM.D. F.R.C.P.

Division of Liver Diseases, The Mount Sinai School of Medicine

Box 1104, One Gustave L. Levy Place, New York, NY 10029

Email: jawad.ahmad@mountsinai.org